Features Pricing Learn Reverse Splits Tracker Shelf & ATM Tracker Warrant Tracker PIPE Deal Tracker Weekly Report FAQ API Sign In →
36 /100
MEDIUM RISK
Score updated Oct 13, 2026

AQST — Aquestive Therapeutics, Inc. Dilution Risk Tracker

Track AQST dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track AQST — Get alerts when the score changes →

As of October 13, 2026, Aquestive Therapeutics, Inc. (AQST) has a DilutionWatch DilutionScore of 36/100, rated MEDIUM dilution risk. Aquestive Therapeutics, Inc. has a market capitalization of $603.71M, 125.51M shares outstanding, 181 institutional holders tracked.

This page includes automatically generated factual summaries from DilutionWatch data. It is not financial advice, not investment research, and not a recommendation. Do your own research. Read the full disclaimer and terms of service.

Score Breakdown

📋 Offering Ability
46
💰 Cash Runway
10
📊 Float Risk
12
⚠️ Warrant Exposure
40
🔄 Convertible Debt
40

Dilution Forecast

☀️
Clear
No significant dilution signals
model est. 0%
No significant dilution signals detected for AQST.
🔔 Track AQST — Get forecast alerts →

Market Data

Market Cap$603.71M
Shares Outstanding125.51M
Float114.54M
Cash$98.49M
Debt$55.03M
Short InterestN/A

Source-Backed Evidence Depth

This public preview uses stored DilutionWatch fields and linked SEC/market records only. Missing values are not estimated.

FieldCurrent ValueBasis
DilutionScore36/100DilutionWatch score record
Shares Outstanding125.51MVerified float table or market cache
Public Float114.54MVerified float table or market cache
Market Cap$603.71MMarket data cache
Cash Runway29.7 monthsDilutionWatch score inputs
Shelf CapacityNone in current score inputsSEC-derived dilution fields
ATM CapacityNone in current score inputsSEC-derived dilution fields
Outstanding WarrantsNone in current score inputsSEC-derived dilution fields

Recent source-backed SEC insight records available on this page: 6.

Recent SEC source mix: 3 2, 4 3, XBRL 1.

The page does not infer future share issuance, financing probability, cash needs, management intent, or price impact when source fields are absent.

Institutional Holdings

QoQ: ↑ 2.4% shares (2026Q1 vs prior)
181 institutional holders · 79.04M shares
#1 Bratton Capital Management, L.P. 9.81M shares
#2 BlackRock, Inc. 7.51M shares
#3 RTW INVESTMENTS, LP 7.43M shares
+ 17 more holders Sign up free to view →

Institutional holder totals are aggregated from ownership filings and may use a different share basis or reporting date than public float. They are not a reconciliation against tradeable float.

Short Interest

Short Interest28.75M
Days to Cover13.1
% of Float25.1%
FINRA data as of Sep 30, 2026

Recent SEC Activity

xbrl XBRL WARRANT 2026-08-11
3 FORM3 2026-04-10
4 INSIDER TRANSACTION 2026-03-11
3 FORM3 2026-03-11
4 INSIDER TRANSACTION 2026-03-11
Full SEC filing analysis available with free account →

Recent News

No recent news available for this ticker.

Factual AQST Dilution Snapshot

Aquestive Therapeutics, Inc. (AQST) has a DilutionScore of 36/100, rated Medium dilution risk. Score date: October 13, 2026.

This automatically generated snapshot is assembled from stored DilutionWatch data fields and may contain data-source errors or omissions. It is not financial advice, not investment research, and not a recommendation. Do your own research and review the full disclaimer and terms of service.

DilutionScore History — Last 90 Days

AQST's DilutionScore is currently 36/100 (Medium risk), with 2 score changes tracked over 89 days. The score improved from 33/100 (Medium risk).

Period Score Risk Level Duration
Sep 30 – Oct 13, 202636/100MEDIUM14 days
Sep 16 – Sep 29, 202633/100MEDIUM14 days
Jul 16 – Sep 15, 202632/100MEDIUM61 days

Score recalculated daily from SEC filings and market data. Sign up free for real-time score change alerts.

Share Dilution History

AQST shares outstanding have increased 2.8% from 122.00M (Mar 2026) to 125.45M (May 2026). Each increase represents potential dilution to existing shareholders.

Date Shares Outstanding Public Float Change
May 30, 2026125.45M114.54M▼ 0.13%
May 22, 2026125.45M114.68M▼ 0.09%
May 18, 2026125.45M114.78M▼ 6.08%
May 17, 2026125.45M122.20M▲ 5.47%
May 15, 2026125.45M115.86M▲ 2.91%
May 10, 2026124.28M112.58M▲ 1.96%
May 07, 2026124.28M110.42M▲ 0.19%
May 04, 2026124.28M110.21M▼ 1.33%
Mar 27, 2026122.05M111.69M▼ 0.09%
Mar 23, 2026122.05M111.78M▲ 0.02%
Mar 14, 2026122.00M111.76M▼ 0.07%
Mar 13, 2026122.00M111.84M▼ 0.09%

Share counts sourced from verified regulatory filings. Increases indicate dilution events.

Track AQST Dilution Risk in Real-Time
DilutionWatch monitors SEC filings 24/7 and alerts you the moment AQST files a shelf registration, ATM offering, warrant notice, or convertible note. Free tier available — no credit card required.
Start Tracking AQST — Free
Email alert within minutes of any SEC filing Daily DilutionScore™ recalculation Score history & trend tracking Tracks 8,000+ tickers simultaneously

Related Stocks — MEDIUM Risk

Other MEDIUM dilution risk stocks tracked by DilutionWatch with similar profiles:

→ Biotech / Pharma sector dilution risk overview

Browse all 8,490+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
More Research for AQST
AQST FDA Catalyst Timeline & Biotech Grade — BiotechSigns

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.